Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.

@article{Borner2002PatientPA,
  title={Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.},
  author={Markus M. Borner and Patrick Schoffski and Ronald de Wit and Francesco Caponigro and Giuseppe Comella and Aar{\'o}n Sulkes and Gudrun A. Greim and Godefridus J. Peters and Kasper van der Born and Jantien Wanders and Richard F De Boer and Claudio Martin and Pierre Fumoleau},
  journal={European journal of cancer},
  year={2002},
  volume={38 3},
  pages={349-58}
}
The aim of this study was to determine the patient's preference for oral UFT/leucovorin (LV) or intravenous (i.v.) 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options. A total of 37 previously untreated patients with advanced colorectal cancer were randomised to start treatment with either oral UFT 300 mg/m2/day plus oral LV 90 mg/day for 28 days every 5 weeks or i.v. 5-FU 425 mg/m2/day plus LV 20 mg/m2/day for 5… CONTINUE READING
129 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 129 extracted citations

Similar Papers

Loading similar papers…